Azitra's preclinical

$Azitra (AZTR.US)$ The results from Azitra's preclinical studies and ongoing clinical trials appear to be positive:
Preclinical Results: The preclinical data for ATR-12, particularly for Netherton syndrome, has shown promising outcomes. ATR-12, an engineered strain of Staphylococcus epidermidis, effectively delivered the missing LEKTI protein in models of the disorder. Additionally, it significantly reduced markers associated with inflammation and protease activity, which are linked to skin damage in Netherton syndrome. These positive effects support the advancement into clinical trials.
Phase 1b Clinical Trial: The Phase 1b trial is primarily focused on safety and tolerability, but early indications from the preclinical work provide a hopeful outlook. Interim results on safety are expected in early 2025, with full results later in the year, which will provide more insight into ATR-12's potential efficacy.
So far, Azitra's progress reflects encouraging preliminary results, which could lead to impactful treatments if these outcomes hold in the clinical stages.